Meet Our New Board Members: Diana Bernstein


August 3, 2022

Meet Our New Board Members: Diana Bernstein

In this new series, we are introducing the new additions to the OMass Board of Directors following our latest round of financing. The aim is to learn a bit more about our new board members and why they were excited to join OMass’s journey.

Diana is currently a Vice President at Northpond Ventures. Previously, Diana was a senior associate at MRL Ventures fund, the corporate venture fund of Merck & Co, investing in early-stage human therapeutics companies. Prior to that, she was an Associate at Flagship Pioneering, leading projects to conceive and build platform-based therapeutics companies.

What attracted you to OMass initially?

I was initially attracted to OMass by the specialized native mass spec approach to solve a major unmet need in drug discovery – simultaneously testing both drug function and drug binding in a single experiment. I was also very impressed with how OMass has demonstrated the utility of this technique in exciting targets that have historically been challenging to drug.

What makes OMass unique?

OMass is a unique group of technology-enabled problem solvers. When I visited the company recently, I was amazed going into the lab and seeing all the instruments that have been customized to answer different scientific questions. To me, this speaks to a culture of curiosity, creativity, and unlimited boundaries.

What excites you most about the company over the next couple of years?

Over the next couple of years, I’m tremendously excited to see all the exciting technology OMass has built translate into a drug that will be ready to test in patients!

Tell us a fun fact about yourself.

This summer I visited the Amalfi Coast and Sardinia and it was the best trip I’ve ever been on! See photo of me in Amalfi, and happy to share recommendations.


MORERelated News
From the feeble mouse to powerful therapeutics: Disrupting a key interaction in the pathway to systemic lupus
Our immune system has evolved a defensive armamentarium to combat pathogens; critically including mechanisms that detect and respond to pathogen...
BIA Member spotlight: Meet OMass Therapeutics
In this blog, Ros Deegan, CEO of OMass Therapeutics, a member of the BIA Board and a member of the Prime Ministers 2024 Business...
Inside the Orphan Drug Revolution: The Promise of Patient-Centered Biotechnology
Thousands of rare diseases, most of genetic origin, were long ignored by a pharmaceutical industry that judged them too small...